• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
ATH

ALTERITY THERAPEUTICS LIMITED - News & Media

0.00% ! 1.1¢
Market Cap $100.4M  !
Healthcare Biotechnology
Add to My Watchlist

Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company.... Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. ATH434 has been granted Orphan designation for the treatment of MSA. The Phase II clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage MSA.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Articles & Videos

Alterity wins FDA fast-track for ATH434 – but with 9B shares on issue, impact diluted

Alterity Therapeutics (ASX:ATH), dual-listed on both the ASX and the NASDAQ, is the latest Aussie biotech to win an FDA tick with its drug...

05 May 2025 10:53 (AEST)

Trial for Alterity's neurodegenerative drug ATH434 shows reduced disability

An interim trial testing the effects of ATH434 on patients with MSA has yielded positive results for Alterity.

17 Jul 2024 11:45 (AEST)

Alterity Therapeutics (ASX:ATH) doses first European patient in phase two MSA trial

Alterity Therapeutics (ASX:ATH) has dosed its first patient in Italy as part of its phase two clinical trial in multiple system atrophy (MSA).

08 Mar 2023 09:19 (AEDT)



Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
Add to My Watchlist
(20min delay)
Last
1.1¢ 		Change
0.000(0.00%) 		Mkt cap ! $100.4M
Open High Low Value Volume
1.0¢ 1.1¢ 1.0¢ $60.81K 5.737M

Buyers (Bids)

No. Vol. Price($)
37 16255465 1.0¢
 

Sellers (Offers)

Price($) Vol. No.
1.1¢ 1643984 2
View Market Depth
Last trade - 16.10pm 13/06/2025 (20 minute delay) ?
ATH (ASX) Chart

Top Stories

Resolution's dual-listing to 'expedite growth' – and sets stage for NASDAQ foray

Resolution Minerals (ASX:RML) is on the verge of listing on the OTCQB @ oft called the @Venture Market” over in the States @ as it looks to @expedite growth” and @unlock value” through the bold U.S. index expansion.Listen to the Ho...
'Sure to be busy': Advance's Yuquivo drilling gets off to top start with first-hole hits Advance Metals (ASX:AVM) has started its maiden drilling at the Yoquivo Silver-Gold Project in Mexico with a bang...
Clinuvel shares dip, even as CEO comes back from temp leave After Clinuvel's (ASX:CUV) CEO Dr. Philippe Wolgen took time off back in March to respond to an "acute medical condition," it wasn't...
Zip's stunning comeback: Is this the start of a $14 revival? Just when the market had written it off… Zip Co (ASX: ZIP) has come roaring back to life. The Buy Now, Pay Later company stunned investors last Wednesday with a 15% surge in its share price soon after upgrading its full-year earnings forecast to at least $160 million @ up from $153 million...
HotCopper Highlights, Week 24: Israel boosts Energy; Meeka eyes production & Mag7 back Good Afternoon and welcome to HotCopper Highlights for Week 24 of the year, I’m Jon Davidson. In this segment we look at some of the...
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.